WASHINGTON — The Food and Drug Administration will convene an outside panel of advisers to discuss whether to allow compounding pharmacies to manufacture certain peptides, the agency announced on Wednesday. The meetings will take place July 23 and 24. Another will be held before the end of February 2027.
In 2023, the FDA removed 19 peptides from a list of drugs the agency allows compounding pharmacies to produce. The July panel will discuss whether to add back seven peptides. At a future meeting that has yet to be scheduled, the panel will discuss whether to add back five.
There is limited data on the effectiveness and safety of many of these products, but they have become increasingly popular, promoted by online influencers and health secretary Robert F. Kennedy Jr. The move comes after Kennedy told podcaster Joe Rogan in February that he wanted to make those peptides more accessible.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
